Document Detail

Thoracoscopic lung metastasectomies: a 10-year, single-center experience.
Jump to Full Text
MedLine Citation:
PMID:  23344503     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
INTRODUCTION: The ideal surgical treatment for pulmonary metastasectomy remains controversial. Minimally invasive surgery may offer advantages for quality of life outcomes, with equivalent oncologic long-term results. The purpose of our study was to confirm the validity of the thoracoscopic approach for pulmonary metastasectomy. METHODS: We retrospectively reviewed 164 patients who underwent 212 lung metastasectomies from January 2000 to December 2010. Complete curative pulmonary resections were performed in 159 (96.95 %) cases; 126 patients developed lung metastases from epithelial tumors: 28 from sarcoma, 7 from melanoma, and 3 from germ cell tumors. The mean disease-free interval (DFI) was 38.75 months. Fifty-four patients underwent a major VATS resection (53 thoracoscopic lobectomies and 1 pneumonectomy), and 110 patients underwent a wedge resection/segmentectomy. Lymph node sampling was performed in 117 cases. RESULTS: After a mean follow-up of 38 months, 87 patients (53 %) had died. All resection margins were tumor-free at final pathological examination. Multivariate analysis not confirmed in our series a better prognosis for patients with a particular histologic type and also DFI, age, number of metastases, and type of surgery did not statistically influence long-term survival. CONCLUSIONS: Thoracoscopic surgery is an acceptable procedure, safe and efficacious, with a 5-year overall survival that is equivalent to open surgery.
Authors:
Felice Lo Faso; Luciano Solaini; Rosalba Lembo; Paolo Bagioni; Silvia Zago; Paolo Soliani; Robert D Pascotto
Related Documents :
23433813 - Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (...
22223693 - Sleeve lobectomy after induction chemoradiotherapy.
10650793 - Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by u...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-24
Journal Detail:
Title:  Surgical endoscopy     Volume:  -     ISSN:  1432-2218     ISO Abbreviation:  Surg Endosc     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806653     Medline TA:  Surg Endosc     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Thoracic Surgery Unit, ASL Ravenna, Maria Cecilia Hospital, Via Corriera 1, 48010, Cotignola, Ravenna, Italy, felice_lo_faso@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Surg Endosc
Journal ID (iso-abbrev): Surg Endosc
ISSN: 0930-2794
ISSN: 1432-2218
Publisher: Springer-Verlag, New York
Article Information
Download PDF
© The Author(s) 2013
OpenAccess:
Received Day: 18 Month: 5 Year: 2012
Accepted Day: 25 Month: 10 Year: 2012
Electronic publication date: Day: 24 Month: 1 Year: 2013
pmc-release publication date: Day: 24 Month: 1 Year: 2013
Print publication date: Month: 6 Year: 2013
Volume: 27 Issue: 6
First Page: 1938 Last Page: 1944
PubMed Id: 23344503
ID: 3661047
Publisher Id: 2691
DOI: 10.1007/s00464-012-2691-8

Thoracoscopic lung metastasectomies: a 10-year, single-center experience
Felice Lo FasoAff1 Address: felice_lo_faso@yahoo.com
Luciano SolainiAff1
Rosalba LemboAff2
Paolo BagioniAff1
Silvia ZagoAff3
Paolo SolianiAff1
Robert D. PascottoAff4
Thoracic Surgery Unit, ASL Ravenna, Maria Cecilia Hospital, Via Corriera 1, 48010 Cotignola, Ravenna Italy
Department of Cardiothoracic and Intensive Care, Istituto Scientifico S. Raffaele, Via Olgettina 60, 20132 Milan, Italy
Department of Pathology, ASL Ravenna, Ospedale S. Maria delle Croci, Viale Randi 5, 48121 Ravenna, Italy
Heart to Heart Mission, 6910 Old Whiskey Creek Drive, Fort Myers, FL 33919 USA

In recent years, lung metastases have been considered an area of interest in many discussions between surgeons to identify the best surgical approach [1]. An important study that assessed the long-term results of pulmonary metastasectomy was based on the International Registry of Lung Metastases [2]. This large registry study revealed that complete resectability, disease-free interval (DFI), and number of metastases were independent prognostic factors. Today, the majority of surgeons prefer metastasectomy by open approach to achieve bimanual lung palpation and to find and resect undetected lesions [3, 4]. In fact, the reliance on computed tomographic (CT) scanning to identify all pulmonary metastases has been criticized [5], and many surgeons prefer an open surgical approach. However, latest generation of CT scanners is superior for the detection of metastatic pulmonary nodules [6]; however, the clinical significance of these nonimaged, resected malignant nodules is unknown, and it is unclear whether the resection of these nodules improves survival. Based on these data, others surgeons use video-assisted thoracoscopic surgery (VATS) or robotic techniques for pulmonary metastasectomy, saving the patient the morbidity of thoracotomy and offering advantages in quality of life, probably with equivalent oncologic outcomes.

We started to perform VATS surgery in 1992 for the treatment of all the thoracic diseases, and thoracoscopic surgery had been favorably performed on patients who had a solitary or multiple lesions. Generally, the pulmonary metastasis was resected by pulmonary wedge resection, when it was located in the periphery of the lung, and by segmentectomy or lobectomy, when it was deep in the parenchyma [7, 8].

In this study, performed in a single-center in the past 10 years, we review our experience in the thoracoscopic surgical approach of lung metastases to evaluate whether a less invasive approach is advisable in these patients, in terms of resectability, long-term survival, and perioperative course.


Patients and methods

We retrospectively reviewed 164 patients who underwent to 212 thoracoscopic lung metastasectomies with curative intent from January 2000 to December 2010 at the Thoracic Surgery Unit of ASL Ravenna, Ravenna, Italy, and data were retrieved from individual medical records. All patients included in the analysis had the following criteria: the primary tumor is controlled (or controllable); there is no other distant disease; complete resection of pulmonary lesions is achievable with adequate pulmonary reserve; and there are no effective medical therapies. Surgeries performed for incomplete resection, biopsy-only, and/or other diagnostic purpose were excluded.

Patients were considered eligible for curative surgery on the basis of traditional staging with chest radiograph, bronchoscopy, and thoracic/abdominal/brain CT. All 164 patients were investigated by CT scan, performed not later than 30 days from the surgery, and 84 patients also were evaluated by positron emission tomography (PET)/CT with fluorodeoxyglucose.

DFI was defined as the time between treatment of the primary tumor and the diagnosis of metastases. Ninety-seven patients had a single-lung metastasis and 67 had multiple lesions. We had three groups with different number of lesions (Table 1).

We performed a total of 212 thoracoscopic metastasectomies with 54 thoracoscopic lobectomy and 158 thoracoscopic wedge resections/segmentectomy. Lymph node sampling was obtained in 117 cases.

Surgical technique

All patients were operated on under general anesthesia with double-lumen endotracheal intubation. All were positioned in the lateral decubitus and in most cases, three ports were sufficient to achieve the thoracoscopic resection: one port for a 10-mm, 30° thoracoscope and two working ports for endoscopic instruments (endoscopic stapler or ultrasonic dissector). For major pulmonary resections, a utility mini-thoracotomy (4–5 cm) without rib spreader was added. All specimens were placed in an endoscopy bag and retrieved through anterior port or the minithoracotomy [7, 8].

Statistical analysis

Patient characteristics are reported as means ± standard deviations or n (%), as appropriate. Continuous variables of patients with discordance and those without were compared with independent t tests. The chi-squared or Fisher’s exact test was used for categorical variables.

Overall survival (OS) was defined as the time from date of surgery to death due to any cause. The Kaplan-Meier method was used to estimate survival curves.

Univariate and subsequent multivariate binary logistic regression analyses were performed to identify independent factors. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) also are indicated. A two-sided P value <0.05 was considered significant. All statistical analyses were performed with the STATA software (version 11.1; Texas USA).


Results

After a mean follow-up of 38 months, 77 (47 %) patients are alive (Fig. 1). Complete curative resection was obtained in 159 patients (96.95 %; Fig. 2).

One hundred patients (61 %) were men and 64 (39 %) were women. Mean age was 64 years (±14.4). Primary tumors were classified into four histological categories: epithelial, sarcoma, melanoma, and germ cell tumors. A total of 126 (77 %) patients developed metastases from epithelial tumors, 28 (17 %) developed from sarcoma, 7 (4 %) developed from melanoma, and 3 (1.8 %) from germ cell tumors (Table 1).

A total of 143 patients (87 %) underwent a single procedure (including six cases of bilateral planned thoracoscopic surgery within 30 days), and 21 patients (13 %) underwent multiple metastasectomies (redo surgery for 8 patients or contralateral surgery but later than 30 days for 13 patients). We performed a total of 212 metastasectomies with thoracoscopic lobectomy in 53 patients and thoracoscopic pneumonectomy in 1:136 wedge resections and 22 segmentectomies.

Nodal metastases were discovered in 20 cases (12 %); in 95 patients (58 %) nodes were negative. Node sampling was not performed in 49 (30 %) patients. All resection margins were tumor-free at final pathological examination.

We had no cases of local recurrence, defined as a tumor relapse at the site of the staple line. There were no intraoperative complications in any of the 164 VATS patients. The most common postoperative minor complications were arrhythmia, hydrothorax, pleural effusion, and air leak (Table 2).

Major complications occurred in four patients (2.4 %); two patients developed hemothorax (requiring one thoracoscopic drainage and the other a thoracotomy), two patients developed respiratory insufficiency and required admission to intensive care unit for 3 and 3 days. There were no postoperative deaths.

Conversion from VATS to thoracotomy occurred in 10 patients (6.5 %): four cases for pleural adhesion, four cases of diffuse metastatic disease, and two for mediastinal and hilar adenopathies.

There were no postoperative deaths, and the mean hospital stay after surgery was 5 days (interquartile range 4–8). One hundred twenty-three patients were admitted to the intensive care unit after the surgery with a mean stay of 1 day (range 1–5 days).

Multivariate analysis (Table 3) not confirmed in our series that patients with a particular histologic type (primary tumor histology, Fig. 3) had a better prognosis (for example, patients with melanoma or sarcoma in our series had no a worse prognosis than those with epithelial tumors). DFI (Fig. 4), nodal status (Fig. 5), epithelial tumors (Fig. 6), number of metastesectomies (Fig. 7), and number of procedures (Fig. 8) did not statistically influence long-term survival.

Moreover, patients who underwent anatomical pulmonary resection (segmentectomy/lobectomy) compared with those who underwent wedge resection did not show any significant difference in long-term survival (Fig. 9).


Discussion

The surgical approach to lung metastases remains highly variable. The choice of approach to pulmonary resection depends more on surgical training and personal conviction than on scientific basis. Certainly, the surgeon who operates on patients affected by advanced disease and history of pulmonary metastases has a moving target in terms of surgical approaches and systemic therapies [9]. Some authors prefer lung palpation during the operation to find and resect undetected lesions. According to previous reports, approximately 20 % of additional malignant nodules could be detected by manual palpation than by preoperative chest CT scan, but the clinical significance of these nonimaged, resected, malignant nodules is unknown [10, 11]. Other surgeons prefer minimally invasive surgery to perform pulmonary metastasectomy and VATS procedure can be performed with less morbidity and faster recovery. Potential advantages of the minimally invasive approach include smaller incisions, less postoperative pain, shorter length of stay, fewer adhesions at reoperation, and better compliance with adjuvant therapies if indicates. The initial data indicate that survival rates do not seem to significantly differ if the patients undergo VATS or open surgery [1214]. Currently, there is no scientific evidence that resection of pulmonary metastases at the time they become radiographically apparent is any less efficacious than open procedures that remove all nodules, benign and malignant, before their radiologic identification. Besides, in open surgery there is the added morbidity of resecting benign nodules (approximately 50 % of nodules palpated), and the complete resection of all palpable metastatic nodules by open surgery is a not a complete biologic resection of all metastatic deposits [15].

Based on our experience, we believe that a surgeon with a large experience in VATS surgery has the ability to achieve complete resection; the ability of complete surgical excision of the metastatic nodules has been shown to be the most significant prognostic factor in the literature. This present study emphasizes the concept that in patients with lung metastases, the biology of the tumor is more important than the strategy of resection. In our thoracoscopic surgical experience, complete curative pulmonary resections were performed in 159 (96.95 %) cases and all resection margins were tumor-free at final pathologic examination. We had no a local recurrence (a tumor relapse at the staples site), and after a mean follow-up of 38 months, 77 (47 %) patients are alive and the overall survival is comparable with that of conventional open surgery. However, multivariate analysis in our study failed to identify any parameter that could statistically influence the long-term survival.

The recent development of multidetector row CT technology has made it possible to detect smaller-sized pulmonary nodules with excellent resolution during a single breath hold and to reconstruct CT images at a thickness of 1 mm. This new CT technology could improve the accuracy of CT scan in the detection of lung metastases and could be a substitute for manual palpation in pulmonary metastasectomy.

In case of recurrence of disease, a minimally invasive approach may be efficaciously repeated with low morbidity in the same patient, with a long-term outcome that is comparable with that after resection by thoracotomy. However, there is no evidence to suggest that the timing of resection of nodules that would be missed at thoracoscopic resection (which are usually <5 mm in diameter) is critical to the final outcome and, as we know, second resection do not adversely affect the overall outcome of patients with metasynchronous detected lesions. Thoracoscopic surgery may be favored in selected patients (for example those with a long DFI, or with a peripherally located nodule, or with several comorbidities, etc.), and we believe that the patient needs to be aware of all surgical options, with their advantages and limitations, and the best approach should be selected together with the surgeon.

For the future, there is need for prospective, clinical trials, performed in a multicenter setting, to obtain adequate answers about the best surgical approach for these patients, perhaps even with new CT technology use. Besides, is very important for the new generations of thoracic surgeons obtain an adequate training in thoracoscopic surgery, to ensure experience and familiarity also with a minimally invasive pulmonary metastasectomy.


Disclosures

Drs. Felice Lo Faso, Luciano Solaini, Silvia Zago, Paolo Bagioni, Paolo Soliani, Robert Pascotto, and Miss Rosalba Lembo have no conflict of interest or financial ties to disclose.


References
1.. Kaifi JT,Gusani NJ,Deshaies I,Kimchi ET,Reed MF,Mahraj RP,Staveley-O’Carroll KF. Indications and approach to surgical resection of lung metastasesJ Surg OncolYear: 2010102218719510.1002/jso.2159620648593
2.. Pastorino U,Buyse M,Friedel G. Long-term results of lung metastasectomy: prognostic analysis based on 5206 casesJ Thoracic Cardiovasc SurgYear: 1997113374910.1016/S0022-5223(97)70397-0
3.. Cerfolio RJ,McCarty T,Bryant AS. Non-imaged pulmonary nodules discovered during thoracotomy for metastasectomy by lung palpationEur J Cardiothoracic SurgYear: 20093578679110.1016/j.ejcts.2009.01.012
4.. McCormack PM,Bains MS,Begg CB,Burt ME,Downey RJ,Panicek DM,Rusch VW,Zakowski M,Ginsberg RJ. Role of Video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trialAnn Thorac SurgYear: 19966221321710.1016/0003-4975(96)00253-68678645
5.. Parsons AM,Ennis EK,Yankaskas BC,Parker LA Jr,Hyslop WB,Detterbeck FC. Helical computed tomography inaccuracy in the detection of pulmonary metastases: can it improved?Ann Thorac SurgYear: 2007841830183610.1016/j.athoracsur.2007.06.06918036893
6.. Kang MC,Kang CH,Lee HJ,Goo JM,Kim YT,Kim JH. Accuracy of 16-channel multi-detector row chest computed tomography with thin sections in the detection of metastatic pulmonary nodulesEur J Cardiothorac SurgYear: 20083347347910.1016/j.ejcts.2007.12.01118222091
7.. Solaini L,Prusciano F,Bagioni P,Di Francesco F,Basilio Poddie D. Video-assisted thoracic surgery(VATS) for major pulmonary resections. Present experienceEur J Cardiothorac SurgYear: 200120343744210.1016/S1010-7940(01)00850-811509260
8.. Solaini L,Prusciano F,Bagioni P,Di Francesco F,Solaini L,Poddie DB. Video-assisted thoracic surgery (VATS) of the lung: analysis of intraoperative and postoperative complications over 15 years and review of literatureSurg EndoscYear: 200822229831010.1007/s00464-007-9586-017943372
9.. Rusch VW. Pulmonary metastasectomy: a moving targetJ Thorac OncolYear: 201056 Suppl 2S130S13110.1097/JTO.0b013e3181dca26820502246
10.. Cerfolio RJ,Bryant AS,McCarty TP,Minnich DJ. A prospective study to determine the incidence of non-imaged malignant pulmonary nodules in patients who undergo metastasectomy by thoracotomy with lung palpationAnn Thorac SurgYear: 2011911696170110.1016/j.athoracsur.2011.02.07521619965
11.. Margaritora S,Porziella V,D’Andrilli A,Cesario A,Galetta D,Macis G,Granone P. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach?Eur J Cardiothorac SurgYear: 2002211111111410.1016/S1010-7940(02)00119-712048094
12.. Nakas A,Klimatsidas MN,Entwisle J,Martin-Ucar AE,Waller DA. Video-assisted versus open pulmonary metastasectomy: the surgeon’s finger or the radiologist’s eye?Eur J Cardiothorac SurgYear: 20093646947410.1016/j.ejcts.2009.03.05019464921
13.. Gossot D,Radu C,Girard P,Le Cesne A,Bonvalot S,Boudaya MS,Validire P,Magdeleinat P. Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach?Ann Thorac SurgYear: 20098723824410.1016/j.athoracsur.2008.09.03619101304
14.. Carballo M,Maish MS,Jaroszewski DE,Holmes CE. Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort studyJ Cardiothorac SurgYear: 200924413
15.. Sonett JR. VATS and thoracic oncology: anathema or opportunity. Video-assisted thoracic surgeryAnn Thorac SurgYear: 19996879579610.1016/S0003-4975(99)00593-710509963

Figures

[Figure ID: Fig1]
Fig. 1 

Patients survival



[Figure ID: Fig2]
Fig. 2 

Completeness of resection



[Figure ID: Fig3]
Fig. 3 

Histology



[Figure ID: Fig4]
Fig. 4 

Disease Free Interval



[Figure ID: Fig5]
Fig. 5 

Nodal Status



[Figure ID: Fig6]
Fig. 6 

Epithelial tumors



[Figure ID: Fig7]
Fig. 7 

Number of metastasectomies



[Figure ID: Fig8]
Fig. 8 

Number of surgeries



[Figure ID: Fig9]
Fig. 9 

Surgery



Tables
[TableWrap ID: Tab1] Table 1 

Clinical characteristics


Predictor variables Overall (%) Alive (%) Death (%) P value
No. of patients 164 (100) 77 (46.95) 87 (53.05)
 Sex
  Male 100 (60.98) 48 (62.34) 52 (59.77) 0.7
  Female 64 (39.02) 29 (37.66) 35 (40.23)
Age (mean ± SD) 64.17 ± 14.4 65.18 ± 13.98 63.27 ± 14.78 0.4
 Histology
  Sarcoma 28 (17.07) 11 (14.29) 17 (19.54) 0.2
  Melanoma 7 (4.27) 4 (5.19) 3 (3.45)
  Germ cell tumors 3 (1.83) 0 3 (3.45)
  Epithelial 126 (76.83) 62 (80.52) 64 (73.56)
   Colorectal 99 (78.57) 51 (82.26) 48 (75) 0.4
   Breast 14 (11.11 5 (8.06) 9 (14.06)
   Urothelial 3 (2.38) 1 (1.61) 2 (3.13)
   Gynecological 2 (1.59) 2 (3.23) 0
   Head-neck 8 (6.35) 3 (4.84) 5 (7.81)
Metastasis
 1 97 (59.15) 44 (57.14) 53 (60.92) 0.3
 2–3 50 (31.71) 28 (36.36) 24 (27.59)
 4+ 17 (9.15) 5 (6.49) 10 (11.49)
Surgery
 Wedge/segmentectomy 136 (68) 55 (71.43) 55 (63.22) 0.2
 Lobectomy 54 (32.93) 22 (28.57) 32 (36.78)
Procedure
 Single procedure 143 (87.2) 69 (89.91) 74 (85.06) 0.4
 Redo 8 (10.39) 13 (14.94) 21 (12.8)
Nodal status
 Negative 95 (57.93) 51 (66.23) 44 (50.57) 0.09
 Positive 20 (12.2) 6 (7.79) 14 (16.09)
 Unknown 49 (29.88) 20 (25.97) 29 (33.3)

[TableWrap ID: Tab2] Table 2 

Minor postoperative complications


Arrhythmia 10
Pleural effusion 7
Prolonged air leak 7
Transfusion 6
Postobstructive pneumonia 3

[TableWrap ID: Tab3] Table 3 

Multivariate analysis for overall survival after pulmonary metastectomy


Variable HR (95% CI) P
Resection
 R0 0.53 (0.16–1.71) 0.29
 R1 1
DFI
 Simultaneous (mo) 1.25 (0.62–2.52) 0.52
 1–12 1.00
 12–36 0.77 (0.4–1.46) 0.43
 >36 1.06 (0.6–1.849 0.83
Sex
 Men 1
 Women 0.81 (0.51–1.28) 0.38
Age (years)
 <60 1
 60–69 0.61 (0.22–1.67) 0.33
 70–79 0.90 (0.32–2.47) 0.83
 >80 1
Metastasis
 1 1
 2–3 0.74 (0.44–1.22) 0.24
 >4 1.46 (0.68–3.12) 0.32
Histology
 Epithelial 1
 Sarcoma 0.9 (0.5–1.62) 0.74
 Melanoma 1.46 (0.35–6.07) 0.59
 Germ cell 1.11(0.34–3.61) 0.85
Surgery
 Wedge resection 1
 Lobectomy/segmentectomy 0.97 (0.61–1.53) 0.46
Nodal status
 Negative 1
 Positive 1.37 (0.74–2.53) 0.3
 Unknown 1.13 (0.68–1.88) 0.63


Article Categories:
  • Article

Keywords: Keywords Pulmonary metastasis, Surgical resection, VATS surgery, Morbidity, Minimally invasive, CT scan technology.

Previous Document:  Raman-on-chip device and detection fibres with fibre Bragg grating for analysis of solutions and par...
Next Document:  Sleeve gastrectomy in older obese patients.